Multiple sclerosis

Advances in Experimental Medicine and Biology

Volumn 724, Issue , 2012, Pages 222-238

  Miller, Elzbieta ^a,b  

^a Neurorehabilitation Ward   (Poland)

^b KAZIMIERZ WIELKI UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BIOLOGICAL MARKER; CALCITRIOL; CATALASE; CELL ADHESION MOLECULE; CHEMOKINE; CLADRIBINE; COPPER ZINC SUPEROXIDE DISMUTASE; CORTICOSTEROID; CYTOKINE; GLATIRAMER; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; MANGANESE SUPEROXIDE DISMUTASE; METALLOPROTEINASE; NATALIZUMAB; NITRIC OXIDE; URIC ACID; VITAMIN D;

ARTICLE; ASTROCYTE; AXONAL INJURY; BLOOD BRAIN BARRIER; DISEASE PREDISPOSITION; EXCITOTOXICITY; GENETIC ASSOCIATION; GLIOSIS; HUMAN; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMBRANE DAMAGE; MICROGLIA; MULTIPLE SCLEROSIS; NERVE FIBER; OLIGODENDROGLIA; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; RELAPSE; REMYELINIZATION; THROMBOCYTE; URIC ACID BLOOD LEVEL; BRAIN; GLIA; INFLAMMATION; METABOLISM; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW;

BLOOD-BRAIN BARRIER; BRAIN; CYTOKINES; HUMANS; INFLAMMATION; MULTIPLE SCLEROSIS; NEUROGLIA; NEURONS; NITRIC OXIDE;

EID: 84859540194     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-0653-2_17     Document Type: Article

References (117)

1. Ramagopalan SV, DobsonR, Meier UC et al. Multiple sclerosis: risk factors, prodromes and potential causal pathways. Lanc Neurol 2010; 9:727-739.
2. Bielekova B, Martin R. Development ofbiomarkers in multiple sclerosis. Brain 2004; 127:1463-1478.
3. MartinR,BielekovaB, HohlfeldRetal. Biomarkers inmultiple sclerosis. Disease Markers 2006; 22:183-185.
4. Miller DH. Biomarkers and surrogate outcomes in neurodegenerative disease: les sons frommultiple sclerosis. NeuroRx 2004; 1:284-294.
5. Pugliatti M, Sotgiu S, Rosati G. The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 2002; 104:182-191.
6. Pugliatti M, Harbo HF, Holmøy T et al. Enviromental risk factors in multiple sclerosis. Acta Neurol Scand Suppl 2008; 188:34-40.
7. Al-Omaishi J, Bashir R, Gendelman HE. The cellular immunology of multiple sclerosis. J Leukoc Biol 1999; 65:444-452.
8. Barnett MH, Parratt JDE, Pollard JD et al. MS: Is it one disease? Internat MS J 2009; 16:57-65.
9. Kurtzke JF. Multiple sclerosis In time and space-geographic clues to causa. JNeurovirol 2000; 6:134-140.
10. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II. Noninfections factors. Ann Neurol 2007; 61:504-513.
11. Munger KL, Ascherio A. Risk factors in development of multiple sclerosis. Exper Rev Clin Immunol 2007; 3:739-748.
12. Levin LI, Munger KL, O'Reilly EJet al. Primary infection with the Epstein-Barr virus and risk of multiple sclerosis 2010; 6:824-830.
13. Oksenberg JR, Barcellos LF. The complex genetic aetiology of multiple sclerosis. J Neurovirol 2000; 6:210-214.
14. Oksenberg JR, Hauser SL. Mapping the human genome with newfound precision. Ann Neurol 2010;67:A8-A10.
15. Baranzini SE. The genetics of autoimmune diseases: a networked perspective. Curr Opin Immunol 2009;21:596-605.
16. Baranzini SE, Wang J, Gibson RA et al. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet 2009; 18:767-778.
17. Al.-Omaishi J, Bashir R, Gendelman HE. The cellular immunology of multiple sclerosis. J Leuk Biol 1999; 65:444-452.
18. Arnett PA. Does cognitive reserve Apple to muli ple sclerosis? Neurology 2010; 74:1934-1935.
19. Rejdak K, Jackson S, Giovannoni G. Multiple sclerosis: a practical overview fot clinicians. Br Med Bull 2010 [Epub ahead of print].
20. Lublin FD. The incomplete nature of multiple sclerosis relapse resolution. J Neurol Sci 2007; 256:14-18.
21. Ontaneda D, Rae D, Rea AD. Management of acute exacerbations in multiple disability progression in sclerosis Ann Indian Acad Neurol 2009; 12:264-272.
22. Lerday E, Yaouanq J, Le Page E et al. Evidence for a two-stages multiple sclerosis. Brain 2010; 10:1-14.
23. Stiive O, Oksenberg J. In: Pagon RA, Bird TC, Dolan CR, Stephens K, editors. GeneReviews [Internet]. Seattle (WA): University ofWashington, Seattle; 1993-2006 [updated 2010 May 11].
24. Bashir K, Whitaker JN. Clinical and laboratory features of primary progressive and secondary progressive MS. Neurology 1999; 53:765-771.
25. Liguori M, Marrosu MG, Pugliatti M et al. Age at onset in multiple sclerosis. Neurol Sci 2000; 21:825-829.
26. Tullman MJ, Oshinsky RJ, Lublin FD et al. Clinical characteristics of progressive relapsing multiple sclerosis. Mult Scler 2004; 10:451-454.
27. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National multiple sclerosis society (USA) advisory committee on clinical trials of new agents in multiple sclerosis. Neurology 1996; 46:907-911.
28. Martinelli V, Rodegher M, Moiola L et al. Late onset multiple sclerosis: clinical characteristics, prognostic factors and differential diagnosis. Neurol Sci 2004; 25 Suppl 4:350-355.
29. Noseworthy JH, Lucchinetti C, Rodriguez M et al. Multiple sclerosis. N Engl J Med 2000; 343:938-952.
30. Polman CH, Reingold SC, Edan G et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005; 58:840-846.
31. Wck-GuttmanB, Jacobs LD. What is New in the treatment of multiple sclerosis? Drugs 2000; 59:401-410.
32. Compston A, Coles A. Multiple sclerosis. Lancet 2002; 372:1221-1231.
33. Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372:1502-1517.
34. Bechmann J, Galea J, Perry VH. What is the blood-brain barier (not)? Trends Immunol 2007; 28:5-11.
35. Ribatti D, Nico B, Crivellato E. Development of the blond-brain barier: a historical point of view. Anat Rec B New Anat 2006; 289:3-8.
36. Nair A, Frederick TJ, Miller SD. Astrocytes in multiple sclerosis: A product of environment. Cell Mol Life Sci 2008; 65:2702-2720.
37. Wolburg H, Lippoldt A. Tightjunctions of the blood-brain barier development, composition and regulation. Vascul Pharmacol 2002; 38:323-337.
38. Abott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barier. Nat Rev Neurosci 2006; 7:41-53.
39. Frank-Cannon TC, Altol T, McAlpine FE. Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodeger 2009; 4:47.
40. Block ML, Hong JS. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 2005; 76(2):77-98.
41. Bradl M, Lassman H. Oligodendrocytes: biology and pathology. Acta Neuropatol 2010; 119:37-53.
42. Bauman N, Pham-Dinh D. Biology of oligodendrocytes and myelin in the mammalian central nervous system. Physiol Rev 2001; 81:871-927.
43. Watzlawik J, Warrington AE, Rodriguez M. Importance of oligodendrocyte protection BBB. Expert Rev Neurother 2010;10(3):441-457.
44. Leoni V. Oxysterols as markers of neurological disease-a review. Scan J Cin Lab Invest 2009; 69:22-25.
45. Stadelmann C, Briick W. Interplay between mechanisms of damage and repair in multiple sclerosis. J Neurol 2008; 255:12-18.
46. GoodinDS. The casual cascade to Multiple sclerosis: a model for MS pathogenesis. PLoSOul2009; 4:4565.
47. Hohlfeld R. Review: 'Gimme five': future challenges in multiple sclerosis. ECTRIMS Lecture 2009. Mult Scler 2010; 16:3-14.
48. Peterson LK, Fujinami RS. Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis. J Neuroimmun 2007; 184:37-44.
49. Racke MK. Immunopathogenesis of multiple sclerosis. Ann Indian Neurol 2009; 12:215-220.
50. Frischer JM, Bramow S, Dal-Bianco A et al. The relation between inflamation and neurodegeneration in multiple sclerosis brains. Brain 2009; 132:1175-1189.
51. Goverman J. Autoimmune T-cell responses in the central nervous system. Nat Rev Immunol 2009; 9:393.
52. Briick W. The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage. J Neurol 2005; 252 Suppl 5:3-9.
53. Christophi GP, Panos M, Hudson ChA et al. Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype. Lab Invest 2009; 89:742-759.
54. Hedegaard Ch J, Krakauer M, Bendtrek LH et al. Thelper cell type 1 (Th1), Th2 and TH17 responses to myelin basic protein and disease activity in multiple sclerosis. Immunology 2008; 125:161-169.
55. DeLuca GC, Wiliams K, Evangelou et al. The contribution of demyelinisation to amonal loss in multiple sclerosis. Brain 2006; 129:1507-1516.
56. Zivadinov R, Cox JL. Neuroimaging in multiple sclerosis. Int Rev Neurobiol 2007; 79:449-474.
57. Benedetti B, Rovaris M, Rocca MA et al. Evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis Mult Scler 2009; 15:789-794.
58. Bernal F, Elias B, Hartung HP et al. Regulation of matrix metalloproteinases and their inhibitors by interferon-p: a longitudinal study in multiple sclerosis patients. Mult Scler 2009; 15:721-727.
59. Zoppo GJ, Milner R. Integrin-matrix interactions in the cerebral microvasculature. Arterioscler ThrombVasc Biol 2006; 26;1966-1975.
60. Arai K, Lo EH. Oligovasular signalig in white matter stroke. Biol Pharm Bull 2009; 32:1639-1644.
61. Goncalves DaSilva A, Yong VW. Matrix metalloproteinase-12 deficiency Horsens relapsing-remitting experimental autoimmune encephalomyelitis in association with cytokine and chemokine dysregulation. Am J Pathol 2009; 174:898-909.
62. Becher B, Durell BG, Noelle RJ. IL-23 produced by CNS-resident cells controls T-cell encephalitogenicity during the effector phase of experimental autoimmune encephalomyelitis. J Clin Invest 2003;112:1186-1191.
63. Bettelli E, OukkaM, Kuchroo VK. T(H)-17 cells in the circle ofimmunity and autoimmunity. Nat Immunol 2007; 8:345-350.
64. Simpson JE, Newcombe J, Cuzner ML et al. Expression of the interferon-gammainducible chemokines IP-10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions. Neuropathol Appl Neurobiol 2000; 26:133-142.
65. Balashov KE, Rottman JB, Weiner HL et al. CCR5(+) and CXCR3(+) T-cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci USA 1999; 96:6873-6878.
66. Schmitz T, Chew LJ. Cytokines and myelination in the central nervous system. ScientificWorldJournal 2008; 8:1119-1147.
67. Kort JJ, Kawamura K, Fugger L et al. Efficient presentation of myelin oligodendrocyte glycoprotein peptides but not protein by astrocytes from HLA-DR2 and HLADR4 transgenic mice. J Neuroimmunol 2006; 173:23-34.
68. Miljkovic D, Momcilovic M, Stojanovic I et al. Astrocytes stimulate interleukin-17 and interferon-gamma production in vitro. J Neurosci Res 2007; 85:3598-3606.
69. Dong Y, Benveniste EN. Immune function of astrocytes. Glia 2001; 36:180-190.
70. Hemmer B, Archelos JJ, Hartung HP. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 2002; 3:291-301.
71. BullardDC, HuX, Schoeb TR et al. Intracellular adhesion molekule-1 expresion required on multiple cell types for development of experimental autoimmune encephalomyelitis. J Immunol 2007; 178:851-857.
72. Sobel RA, Mitchell ME, Fondren G. Interacellular adhesion molecule (ICAM-1) in cellular immune reactions in the human central nervous system. Am J Pathol 1990; 136:1309-1316.
73. Allavena R, Noy S, Andrews M et al. CNS elevation of vascular and not mucosal addressin cell adhesion molecules in patients with multiple sclerosis. Am J Pathol 2010; 176:556-562.
74. Malik M, Chen YY, Kienzle MF et al. Monocyte migration and LFA-1 mediated attachment to brain microvascular endothelial is regulated by SDF-1 alpha though Lyn kinase. J Immunl 2008; 181:4632-4637.
75. Chari DM. Remyelination in multiple sclerosis. Int Rev Neurobiol 2007; 79:589-620.
76. Jakovcevski I, Filipovic R, Mo Z et al. Oligodendrocyte development and the onset of myelination in the human fetal brain. Front Neuroanat 2009; 3:5.
77. Dubois-Dalcq M, Willams A, Stadelmann Ch et al. From fish to man: understanding endogenous remyelination in central nervius system demyelinating diseases. Brain 2008; 131:1686-1700.
78. Chandran S, Hunt D, Joannides A et al. Myelin repair: the role of stem and prekursor cells in multiple sclerosis. Phil Trans R Soc 2008; 363:171-183.
79. Chang A, Smith MC, Yin X et al. Neurogenesis in the chronic lesions of multiple sclerosis. Brain 2008; 131:2366-2375.
80. Ingram G, Hakobyan S, Robertson NP et al. Complement in multiple sclerosis: its role in disease and potential as a biomarker. Clinic Exper Immunology 2008; 155:128-139.
81. Carson MJ. Microglia as leasions between the immune and central nervous systems: functional implications for multiple sclerosis. Glia 2002; 40:218-231.
82. Orhan A, Ullrich O, Infante-Durte C et al. Neuronal damage in brain inflammation. Arch Neurol 2007; 64:185-189.
83. Armstrong AC, Le TQ, Flint NC et al. Endogenous cell repair of chronic demyelination. J Neuropathol Exp Neurol 2006; 65:245-256.
84. Hooper DC, Scott GS, Zborek A et al. Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barier permeability changes, and tissue damage in a mouse model of multiple sclerosis. FASEB 2004; 14:691-698.
85. Gilgun-Sherki Y, MelamedE, OffenD. The role of oxidative stress in the pathogenesis ofmultiple sclerosis. The need for the effective antioxidant therapy. J Neurol 2004; 251:261-268.
86. Gonsette R. Oxidative stress and excitotoxicity: a therapeutic issue in multiple sclerosis? Mult Scler 2008; 14:22-34.
87. Miller E, Mrowicka M, Zolyhski K et al. Oxidative stress in multiple sclerosis. Pol Merk Lek 2009; 27:499.
88. Miller E, Mrowicka M, Malinowska K et al. Effects of whole body cryotherapy on total antioxidative status and activities of antioxidative enzymes in blood of patients with multiple sclerosis. J Med Invest 2010; 57:168-173.
89. Miller E, Rutkowski M. Contribution and part of main biochemic factors in ischemic insult. Pol Merk Lek 2006; 117:261-264.
90. Calabrese V, Cornelius C, Rizzarelli E et al. Nitric oxide in cell survival: ajams molecule. Antioxid Redox Signal 2009; 11:2717-2739.
91. Trapp BD, Sys PK. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol 2009; 8:280-291.
92. Bishop A, Hobbs KG, Equchi A et al. Differential sensivity of oligodendrocytes and motor neurons to reactive nitrogen species: implications for multiple sclerosis. J Neurochem 2009; 109:93-104.
93. Clarcson A, Sutherland B, Appelton I. The biology and pathology of hypoxia-ischaemia-induced brain damage: an update. Arch Immunol Ther Exp 2005; 53:213-225.
94. Muniandy S, Ovist R, Ong Siok Yan G et al. The oxidative stress of hyperglycemia and the inflammatory process in endothelial cells. J Investigating Med 2009; 56:6-10.
95. Koch M, Mostert J, Arutjunyan AV et al. Plasma lipid peroxidation and progression of disability in multiple sclerosis. Eur J Neurol 2007; 14529-14533.
96. Drulovic J, DujmovicI, StojsavljevicNet al. Uric acid levels in serum from patients with multiple sclerosis. J Neurol 2001; 248:121-126.
97. Hooper DC, Scott GS, Zborek A et al. Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation. The FASEB J 2000; 14:691-698.
98. Rentzos M, Nikolaou C, Anagnostouli M et al. Serum uric acid and multiple sclerosis. Clin Neurol Neurosurg 2006; 108:527-531.
99. Pierrot-Deseilligny C. Clinical implications of a possible role of vitamin D in multiple sclerosis. J Neurol 2009; 256:1468-1479.
100. Debouverie M. Gender as a prognostic factor and its impact on the incidence of multiple sclerosis in Lorraine, France. J Neurol Sci 2009; 286:14-17.
101. Smolders J, Damoiseaux J, Menheere P. Vitamin D as an immune modulator in multiple sclerosis. J Neuroimmunol 2008; 194:7-17.
102. Correale J, Célica Ysrraelit M, Inés Gaitán M. Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain 2009:132; 1146-1160.
103. Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence? Clinical implications of a possible role of vitamin D in multiple sclerosis. Br J Nutr 2003; 89:552-572.
104. SheremataW, Jy W, Horstman LL et al. Evidence of platelet activation in multiple sclerosis. JNeuroinflam 2008; 5:27.
105. Horstman LL, Jy WW, Zavadinov R et al. Role of platelets in neuroinflammation: a wide-angle perspective JNeuroinflam 2010;7:10.
106. Wachowicz B, Rywaniak JZ, Nowak P. Apoptic matkers in human blood platelets treated with peroxynitrite. Platelets 2008; 19:624-635.
107. Putnam TJ. Studies in multiple sclerosis (iv) 'encephalitis' and sclerotic plaques produced by venular obstruction. Arch Neurol Neurosurg Psychiat 1935; 33:929-940.
108. Losy J, Niezgoda A, Wender M. Increased serum levels of solube PECAM-1 in multiple sclerosis patients with brain gadolinum enhancing lesions. J Neuroimmunol 1999; 99:169-172.
109. Van Walderveen MA, Barkhof F, Pouwels PJ et al. Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. Ann Neurol 1999; 46:79-87.
110. MartinR,BielekovaB,HohfeldRetal. Biomarkersinmultiple sclerosis. Disease Markers 2006; 22:183-185.
111. Seven A, Aslan M. Biochemical and immunological markers of multiple sclerosis. Turk J Biochem 2007; 32:112-119.
112. Markowitz CE. The current landscape and unmetneeds in multiple sclerosis. Am J Manage Care 2010; 16:211-218.
113. Vyshkina T, Kalman B. Autoantibodies and neurodegeneration in multiple sclerosis. Lab Investig 2008; 88:796-784.
114. McDonagh M, Dana T, Chan BKS et al. Drug Class Review on Disease-modifying Drugs for multiple sclerosis: Final Report. [Internet] 2007; Drug Class Reviews.
115. Abstracts: 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 15th Annual Conference ofRehabilitation in MS (RIMS). Mult Scler 2010; 16:S7.
116. Murphy JA, Harris JA, Cramnage AJ. Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis. Neuropsychiatr Dis Treat 2010; 6:619-25.
117. Rasova K, Feys P, Henze T et al. Emerging evidence-based physical rehabilitation for multiple sclerosis-Towards an inventory of current content across Europe. Health and Ouality of Life outcomes 2010; 8:76.